

## Supplementary Online Content

Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. *JAMA Dermatol*. Published online October 21, 2015. doi:10.1001/jamadermatol.2015.2707.

### **eTable.** Patients' Characteristics

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Patients' Characteristics

Variable	All patients (N=67)	vitiligo (N=17)	non vitiligo (N=50)	p*
<b>age (years; median,range)</b>	54 (20-74)	57 (30-72)	53 (20-74)	0.24
<b>female/male ratio</b>	29/38 (0.6)	5/12 (0.2)	24/26 (0.9)	0.26
<b>breslow thickness (mm; median,range)</b>	2.6 (0.6-9)	3.1 (0.6-7)	4.1 (1.1-9)	0.34
<b>primary site</b>				0.47
cutaneous	56 (83.6)	16 (94.1)	40 (80)	
head/neck	13 (19.4)	2 (11.7)	11 (22)	
trunk	11 (16.4)	3 (17.6)	8 (16)	
lower and upper limbs	25 (37.3)	9 (52.9)	16 (32)	
acral	7 (10.4)	2 (11.8)	5 (10)	
mucosal	4 (6)	1 (5.9)	3 (6)	
unknown	7 (10.4)	–	7 (14)	
<b>BRAF mutation status</b>				0.15
mutant	22 (32.8)	3 (17.6)	19 (38)	
nonmutant	45 (67.2)	14 (82.4)	31 (62)	
<b>M staging of extent of metastasis</b>				0.19
M0	3 (4.5)	–	3 (6)	
M1a	14 (20.9)	6 (35.2)	8 (16)	
M1b	4 (6)	–	4 (8)	
M1c	46 (68.6)	9 (52.9)	37 (74)	
<b>History of cytotoxic chemotherapy</b>	30 (44.8)	9 (52.9)	21 (42)	0.57
<b>History of immunotherapy (excluding adjuvant treatments)</b>	21 (31.3)	4 (23.5)	17 (34)	0.55
<b>History of targeted agents</b>	21 (31.3)	1 (5.9)	20 (40)	0.01
<b>Number of prior systemic treatments for metastatic disease</b>				0.20
0	27 (40.3)	9 (52.9)	18 (36)	
1	13 (20.9)	1 (5.9)	12 (24)	
2 or plus	27 (40.3)	5 (29.4)	22 (44)	
<b>time since first diagnostic (months;median,range)</b>	41 (2-310)	25 (2-90)	47.5 (2-310)	0.04
Values are n (%) unless otherwise indicated. The stage was classified according to the American Joint Committee on Cancer. Cytotoxic chemotherapy included: carboplatin, cisplatin, dacarbazine, docetaxel, fotemustine, paclitaxel, temozolomide, bortezomib and cyclophosphamide. Immunotherapy included: Ipilimumab and tumor infiltrating lymphocytes (TIL) immunotherapy Targeted agents included sorafenib, trametinib, vemurafenib, dasatinib, oblimersen, dabrafenib * Fischer exact test for categorical variable; Mann-Whitney test otherwise				